Although targeting calcitonin gene related peptide (CGRP) and its receptor with antibodies and antagonists revolutionized migraine therapy, some questions on the long-term application of anti-CGRP treatment, especially in children, adolescent and the elderly are still open [6]. This evidence concerns the gene CALCA and migraine disorder.